[The role of embolization treatment of acute hemorrhage].
137 arteries of 95 patients were treated by transcatheter embolization for massive haemorrhage using Ethibloc, Gelfoam, wire coils and Tissucol (Fibrinogen + Thrombin). The bleeding was secondary to trauma in 23 patients, to neoplasms in 16 patients and to vascular malformations or chronic inflammatory processes in 41 cases. 15 patients were treated for iatrogenic bleeding following surgery. Bleeding was referred to haemoptysis (n = 27), pelvic (n = 24), renal (n = 16) or gastrointestinal haemorrhage (n = 13) as well as several other diseases (n = 15). Most patients were poor surgical candidates. The overall bleeding control rate was 89.5% with a incidence of recurrent bleeding in 14 out of 95 patients (14.7%) treated by re-embolization or surgery. 6 patients died (6.3%) due to intractable haemorrhage, 4 patients (4.2%) died of complications related to embolization procedure (4 x bowel infarction!) and 33 patients (34.7%) died of procedure-unrelated causes such as myocardial infarction, trauma, malignancy or other underlying diseases. 58 patients (61.1%) are still alive (follow-up 16.2 +/- 4.8 months). Significant complications (5.3%) included bowel necrosis (4x) and ischaemia of the spinal cord with incomplete paralysis in one patient. One patient suffered thrombosis of the common iliac artery due to angiography. On the basis of our results, peripheral embolization using Ethibloc can be recommended as palliative treatment for devascularisation of bleeding tumours. Satisfactory results are obtained in haemoptysis, renal and pelvic haemorrhage, but gastrointestinal bleeding should not be occluded by means of Ethibloc because of its considerable risk of bowel infarction.
Görich
J
J
Abteilung Diagnostische Radiologie, Radiologische Universitätsklinik Heidelberg.
Brambs
H J
HJ
Allmenröder
C
C
Roeren
T
T
Brado
M
M
Richter
G M
GM
Kauffmann
G W
GW
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003973:Diatrizoate / Q000627:therapeutic use; D004338:Drug Combinations; D004621:Embolization, Therapeutic; D005227:Fatty Acids / Q000627:therapeutic use; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000628:therapy; D005781:Gelatin Sponge, Absorbable / Q000627:therapeutic use; D006470:Hemorrhage / Q000628:therapy*; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy; D008171:Lung Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010388:Pelvis / Q000098:blood supply; D011409:Propylene Glycols / Q000627:therapeutic use; D015028:Zein / Q000627:therapeutic use
D004338:Drug Combinations; D005227:Fatty Acids; D015718:Fibrin Tissue Adhesive; D011409:Propylene Glycols; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution
Zum Stellenwert der Embolisationsbehandlung bei akuten Blutungen.